The anti-diabetic activity of Bifidobacterium lactis HY8101 in vitro and in vivo

Abstract

Aims: The aim of this study was to evaluate the effects of Bifidobacterium lactis HY8101 on insulin resistance induced using tumour necrosis factor-a (TNF-a) in rat L6 skeletal muscle cells and on the KK-A Y mouse noninsulindependent diabetes mellitus (NIDDM) model. Methods and Results: The treatment using HY8101 improved the insulinstimulated glucose uptake and translocation of GLUT4 via the insulin signalling pathways AKT and IRS-1(Tyr) in TNF-a-treated L6 cells. HY8101 increased the mRNA levels of GLUT4 and several insulin sensitivity-related genes (PPAR-c) in TNF-a-treated L6 cells. In KK-A Y mice, HY8101 decreased fasting insulin and blood glucose and significantly improved insulin tolerance. HY8101 improved diabetes-induced plasma total cholesterol and triglyceride (TG) levels and increased the muscle glycogen content. We observed concurrent transcriptional changes in the skeletal muscle tissue and the liver. In the skeletal muscle tissue, the glycogen synthesis-related gene pp-1 and GLUT4 were up-regulated in mice receiving HY8101 treatment. In the liver, the hepatic gluconeogenesis-regulated genes (PCK1 and G6PC) were down-regulated in mice receiving HY8101 treatment. Conclusions: Bifidobacterium lactis HY8101 can be used to moderate glucose metabolism, lipid metabolism and insulin sensitivity in mice and in cells. Significance and Impact of the Study: Bifidobacterium lactis HY8101 might have potential as a probiotic candidate for alleviating metabolic syndromes such as diabetes.

Antihyperglycemic effect of rice husk derived xylooligosaccharides in high‐fat diet and low‐dose streptozotocin‐induced type 2 diabetic rat model

“…To explore the possible antidiabetic mechanisms of XOS, the skeletal glucose uptake was investigated using isolated rat hemidiaphragm. Consistently, cell-free extract of Bifidobacterium lactis HY8101 treatment increased glucose accumulation into TNF-α-induced insulin-resistant rat skeletal muscle cells (Kim et al, 2014). We speculate that the attenuation of plasma glucose level in HFD-STZ-induced T2DM rats could be a consequence of glucose transportation activity in the skeletal muscle.…”

Bifidobacteria possess inhibitory activity against dipeptidyl peptidase-IV

“…; Kim et al . ). More studies are needed to explore the potential anti‐diabetic activity of probiotic Bifidobacteria, as they could provide new adjuncts to existing therapies or lead to the discovery of novel pharmacological compounds.…”

“…Probiotics have emerged as potentially novel and natural therapeutic drugs for controlling diabetes, alleviating hyperglycaemia and increasing insulin sensitivity and in the future could be used as an adjunct in the management of diabetes (Kim et al . ; Miyoshi et al . ; Panwar et al .…”

“…Probiotics have emerged as potentially novel and natural therapeutic drugs for controlling diabetes, alleviating hyperglycaemia and increasing insulin sensitivity and in the future could be used as an adjunct in the management of diabetes (Kim et al 2014;Miyoshi et al 2014;Panwar et al 2014;Razmpoosh et al 2015). Bifidobacteria represent one of the dominant groups of micro-organisms colonizing the human intestine, constituting >1% of the intestinal population in adults and up to 90% of the faecal anaerobic bacteria in breast-fed infants (Mueller et al 2006;Penders et al 2006).…”

“…Bifidobacteria represent one of the dominant groups of micro-organisms colonizing the human intestine, constituting >1% of the intestinal population in adults and up to 90% of the faecal anaerobic bacteria in breast-fed infants (Mueller et al 2006;Penders et al 2006). Certain members of the Bifidobacterium are the most frequently used probiotics because of their health-promoting properties, such as improving the intestinal microbial balance of the host, lowering the risk of gastrointestinal diseases, exerting immunomodulatory effects and controlling glucose metabolism (Russell et al 2011;Fanning et al 2012;Kim et al 2014). More studies are needed to explore the potential anti-diabetic activity of probiotic Bifidobacteria, as they could provide new adjuncts to existing therapies or lead to the discovery of novel pharmacological compounds.…”